Home > News > Abraxis BioScience splits in two
July 5th, 2007
Abraxis BioScience splits in two
Abstract:
The new Abraxis BioScience would become a more highly focused biotechnology company, which would concentrate more on the nab (nanoparticle-albumin bound) technology platform to deliver therapeutics, such as ABRAXANE (albumin-bound paclitaxel), and work towards new and personalized treatments to patients with life-threatening diseases, Soon-Shiong said.
Source:
biopharma-reporter.com
Bookmark:
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013